Testosterone and Heart Disease: TRT and Heart Risk

Introduction

TRT and heart risk is a direct answer: the TRAVERSE trial found that testosterone replacement therapy does not increase major cardiovascular events—heart attack, stroke, or cardiovascular death—in men aged 45 to 80 with confirmed hypogonadism and existing heart disease or high cardiovascular risk.

For over a decade, the question of whether testosterone replacement therapy increases heart risk has generated more heat than light. Underpowered trials, conflicting observational studies, and regulatory warnings created a fog that left clinicians and patients guessing.

The TRAVERSE trial changed that. Published in 2023, it enrolled 5,246 men aged 45 to 80 years with pre-existing or high risk of cardiovascular disease and symptoms of hypogonadism. Each participant required two fasting testosterone measurements below the normal range before randomization. The trial ran long enough and enrolled enough men to produce the first adequately powered, placebo-controlled evidence on testosterone and heart disease.

What it found was non-inferiority: testosterone therapy did not increase major adverse cardiovascular events compared to placebo. That is not the same as proving TRT is safe in all contexts or for all men, but it is the strongest evidence we have for the population studied. Before you decide whether choosing an online TRT clinic or starting treatment makes sense for you, here is what the trial actually measured and what it means.

Problem Statement

For years, men considering testosterone replacement therapy heard two stories. One story said TRT raises heart attack risk. The other said it lowers it. Both came with studies attached, and neither matched the other's numbers.

The confusion started early. Small trials showed no clear pattern. Observational studies — the kind that track who took what and who had an event — pointed toward protection. Five randomized controlled trials involving 940 men found no effect on myocardial infarction risk, with an odds ratio of 0.51 that crossed the line of no difference (95% CI: 0.11–2.31, P = 0.39). Meanwhile, six observational studies tracking 381,924 men suggested TRT reduced heart attack risk, with an odds ratio of 0.59 (95% CI: 0.49–0.70, P < 0.00001). The analysis showed significant inter-study heterogeneity — a Q-value of 47.1 (P < 0.0001) and I² of 77% — which means the studies disagreed with each other more than chance would predict.

Why the Numbers Diverged

The trials were small and short. The observational studies were large but messy — they could not control who started treatment or why. Men with untreated low testosterone often carry other cardiovascular risks: obesity, metabolic syndrome, sedentary behavior. If healthier men chose TRT, the observational data would look protective even if the drug did nothing. If sicker men avoided it, the data would look harmful. Without a large, long, randomized trial in men who actually need the treatment, the question stayed open.

Clinics kept prescribing. Patients kept asking. Regulatory agencies kept issuing warnings based on the small trials and the observational noise. The gap between what the evidence showed and what patients needed to know widened every year. TRAVERSE was designed to close it.

Before choosing any testosterone option, understanding the best online TRT clinic structures and what questions to ask can help you evaluate the quality of monitoring and cardiovascular screening you will receive.

Does TRT Increase Heart Risk? What TRAVERSE Measured

The TRAVERSE trial enrolled 5,246 men aged 45 to 80 years with pre-existing or high risk of cardiovascular disease. Every participant reported symptoms of hypogonadism and required two fasting testosterone measurements below the threshold before randomization. This was not a study of healthy young men experimenting with optimization — it was a cardiovascular safety trial in the population most likely to experience heart events.

The trial was multicentre, randomized, double-blind, and placebo-controlled. The design tested non-inferiority, meaning the question was not whether TRT reduces heart risk, but whether it increases it enough to matter. The primary cardiovascular safety endpoint was the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke. That is the number that matters.

What the Trial Actually Measured

TRAVERSE demonstrated non-inferiority of TRT versus placebo for major adverse cardiovascular events. Testosterone therapy did not significantly increase the risk of death from cardiovascular causes, heart attack, or stroke in this high-risk population. The trial provided robust evidence that TRT does not elevate MACE risk in men who meet the diagnostic criteria for hypogonadism and who have existing cardiovascular disease or elevated cardiovascular risk.

The findings also showed that testosterone therapy effectively mitigated anemia in hypogonadal men, highlighting a dual benefit of increasing red blood cell production while managing cardiovascular risks. This secondary outcome matters because polycythemia is a known risk of TRT, and the trial monitored hematocrit throughout.

Who Was Not Studied

TRAVERSE did not include men with normal baseline testosterone, men under 45, or men without cardiovascular risk factors. It did not test supraphysiologic dosing, anabolic steroid cycles, or gray-market compounded formulations. If you are considering testosterone supplements for men or non-prescription interventions, this trial does not speak to those.

The trial also did not measure outcomes beyond MACE in granular detail. Attention has shifted toward clinically important non-MACE outcomes, notably atrial fibrillation, acute kidney injury, and venous thromboembolism. TRAVERSE was not powered to detect rare events in those categories, and the safety profile of TRT continues to prompt clinical and regulatory scrutiny beyond major cardiovascular events.

What It Costs You in Monitoring

TRAVERSE required two fasting testosterone results before enrollment and continuous monitoring throughout. In practice, that means baseline labs, follow-up at three months, and periodic checks of hematocrit, PSA, and cardiovascular markers. Nobody selling TRT will tell you that monitoring is where the real cost lives — not just in money, but in time and compliance.

The trial's design reflects contemporary practice: test first, test twice, and monitor continuously. If a clinic offers TRT without requiring two morning testosterone measurements and a full panel including hematocrit and PSA, the protocol does not match the evidence base that produced the TRAVERSE findings.

How to Minimize TRT and Heart Risk in Practice

The TRAVERSE trial enrolled men aged 45 to 80 with hypogonadism and either prediabetes or diabetes — a population at higher baseline cardiovascular risk. If you fit that profile, the trial says TRT does not add major cardiovascular events on top of that risk, but it also does not reduce them. That means safe use still depends on monitoring what the trial monitored and discussing what it did not study.

Ask for the Full Panel Before Starting

Before you sign up with any clinic, ask your doctor for total and free testosterone, SHBG, LH, FSH, estradiol, hematocrit and PSA. Two morning results, at least a week apart, confirm the diagnosis. Many telehealth platforms skip LH and FSH, which tell you whether your low testosterone comes from your testicles or your brain. That distinction matters for fertility and for choosing between TRT and alternatives like enclomiphene. If the clinic does not order the full panel, you are guessing.

Know What Monitoring Looks Like

Regular monitoring is not optional. Research shows that online TRT information often fails to describe the need for regular monitoring, leaving patients unaware of what safe use requires. TRAVERSE tracked hematocrit (red blood cell count), PSA (prostate marker), and cardiovascular events over a median of 33 months. Your follow-up should include hematocrit at 3 and 6 months, then annually, because TRT raises red blood cell production and elevated hematocrit increases clot risk. PSA should be checked at baseline and periodically if you are over 40. If your clinic does not schedule these, ask why — or find one that does.

Effective patient education and counseling are essential to improve compliance and treatment outcomes.

Discuss What TRAVERSE Did Not Study

TRAVERSE excluded men with a recent heart attack, stroke, or uncontrolled heart failure. It also excluded men under 45 and men without metabolic disease. If you are younger, healthier, or have recent cardiovascular events, the trial does not tell you whether TRT is safe for you. Ask your doctor whether your history puts you outside the studied population. If it does, the decision requires more caution and closer monitoring than the trial data support.

The trial also did not compare TRT to enclomiphene, clomiphene, or hCG — treatments that raise your own testosterone and usually preserve fertility. If fertility matters to you, TRT is not the only option. Discuss the trade-offs before committing to a treatment that suppresses sperm production. For men who want to avoid prescription therapy entirely, natural testosterone optimization through weight loss, sleep apnea treatment and alcohol reduction still moves the number.

What to Expect from Your Clinic

A clinic that follows evidence-based practice will order the full testosterone panel before prescribing, explain what the numbers mean, discuss monitoring intervals, and tell you the cost in money, time, and fertility. It will not promise you energy, libido, or muscle gains without first confirming hypogonadism. It will not skip hematocrit or PSA checks to keep the subscription price low. If the clinic leads with the price and buries the monitoring, you are paying for convenience, not safety.

Conclusion

The TRAVERSE trial settled a decade-long debate with the first adequately powered, placebo-controlled data on TRT and heart risk. The short answer: no increase in major cardiac events, no elevated stroke risk, and no difference in mortality between testosterone and placebo in men 45 to 80 years old who had pre-existing cardiovascular disease or high cardiovascular risk. That is the finding that addressed the FDA's 2015 safety concern and allowed treatment to continue under clearer terms.

What it means for you: if you meet the trial population — two morning testosterone results below 300 ng/dL, symptoms of hypogonadism, and either known heart disease or multiple risk factors — the cardiovascular safety profile is now documented over a median of 33 months. The trial did not study younger men, men without cardiovascular risk, or men whose testosterone is in the low-normal range. It also did not compare TRT to enclomiphene, clomiphene, or hCG, so the heart-risk question for those alternatives remains open.

Before starting any treatment, test twice on separate mornings, get a full panel that includes LH and hematocrit, and ask your provider whether your profile matches the studied population. If it does not, the decision becomes more individual and the monitoring becomes more important. The free option — weight loss, sleep apnea treatment, alcohol reduction — still moves the number and carries no prescription cost or monitoring burden.

The evidence now says TRT does not increase heart risk in the population that was studied. It does not say TRT is risk-free in all contexts, and it does not replace the need to track hematocrit, blood pressure, and lipid panels while you are on it. If you are considering treatment, read the trial inclusion criteria, compare them to your own labs and history, and choose a clinic or provider that will monitor what the guidelines say to monitor. That is how you use the TRAVERSE data correctly.